NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, has succeeded in raising £500,000 from Syndicate Room and its own investor network, exceeding fundraising targets by 25%.
The funding will enable prototype development for a multi-biomarker diagnostic device, as well as a series of disease-specific multi-biomarker disease panels that are key components of the system. The NALIA platforms will allow rapid, inexpensive, multiplex analysis in the laboratory setting as well as at the point-of-need.
Nigel Davis, NALIA Systems CEO, said: “The company is already well advanced with its revolutionary laboratory multiplex system. This investment will allow us to accelerate prototype development and validation of the next generation point-of-care device. The point of care system will save clinicians and patients a huge amount of time, making healthcare more efficient and cost-effective. Results from NALIA’s proprietary technology can be obtained in less than 20 minutes without needing to be sent off to a laboratory. The evolution of precision, personalised medicine will demand rapid multiple biomarker analysis to enable accurate disease diagnosis and prescription. For the first-time NALIA’s system will offer a rapid, cost-effective approach both to centralised testing and to the near patient market.”
This financial backing will also aid development of NALIA Systems’ custom biomarker panel design service. Custom panels provide researchers with data from all markers of interest, without requiring large amounts of sample, greatly improving productivity.